BUZZ-Sarepta rises after U.S. FDA clears study of muscle-wasting disease drug

Reuters11-25
BUZZ-Sarepta rises after U.S. FDA clears study of muscle-wasting disease drug

**Shares of drug developer Sarepta Therapeutics SRPT.O 2.1% to $19.78 in early trading

** Co says U.S. FDA has approved the start of new study to test whether adding an extra immune-suppressing drug can make its gene therapy for Duchenne muscular dystrophy safer for patients who can no longer walk

** DMD is a rare genetic disorder that causes progressive muscle weakness and loss, mostly in boys and young men

** The early stage trial enrolls ~25 patients who can no longer walk, co says

** Patients will receive co's Elevidys gene therapy plus sirolimus to lower risk of serious liver complications - RNA

** The therapy is approved for children aged four and older who can walk, but not for those unable to walk due to safety concerns - RNA

** Including session's move, stock down ~85% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment